Fathi AT, et al. - Researchers evaluated the safety, tolerability, and activity of vadastuximab talirine, a CD33-targeted antibody-drug conjugate, in combination with hypomethylating agents in frontline acute myeloid leukemia (AML). In the combination cohort of a phase 1 study, vadastuximab talirine was administered intravenously to 53 patients at 10 μg/kg on last day of hypomethylating agent (HMA: azacitidine or decitabine) infusion, in four-week cycles. Outcomes suggest that vadastuximab talirine with hypomethylating agents is active in frontline AML, and lead to high remission rates and protracted myelosuppression in older patients.